Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glofitamab + polatuzumab vedotin + gemcitabine + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
G-Pola-GemOx is an experimental chemoimmunotherapy combination regimen being evaluated for the treatment of relapsed or refractory aggressive B-cell lymphomas. The regimen consists of four active agents: **glofitamab**, a bispecific monoclonal antibody that redirects T-cells to kill B-cells by binding to CD3 and CD20; **polatuzumab vedotin**, an antibody-drug conjugate (ADC) targeting CD79b to deliver the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE); and the chemotherapy doublet **GemOx** (gemcitabine and oxaliplatin). Gemcitabine acts as a nucleoside analog that inhibits DNA synthesis, while oxaliplatin is a platinum-based agent that forms DNA cross-links. This multi-modal approach combines T-cell redirection, targeted cytotoxic delivery, and systemic chemotherapy to overcome resistance in aggressive B-cell malignancies. A Phase 2 trial led by Navy General Hospital, Beijing, is investigating this regimen as an induction therapy.
- Other names
- G-Pola-GemOx regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)B-cell antigen receptor complex-associated protein beta chainDNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on glofitamab + polatuzumab vedotin + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glofitamab + polatuzumab vedotin + gemcitabine + oxaliplatin.